QLH 12016
Alternative Names: QLH-12016Latest Information Update: 10 Aug 2023
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 09 Aug 2023 Qilu Pharmaceutical plans a phase I trial for Prostate Cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in China (NCT05973149)
- 02 Aug 2023 Preclinical trials in Prostate cancer in China (unspecified route)